Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 9.46% is 60% below its 5-year average of 23.86%, near the low end of its 5-year range (9.46%–41.75%).
63.71% below its 12-month average of 26.07%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
9.46%
RETURN ON EQUITY (ROE) AVG TTM
26.07%
RETURN ON EQUITY (ROE) AVG 3Y
24.86%
RETURN ON EQUITY (ROE) AVG 5Y
23.86%
RETURN ON EQUITY (ROE) AVG 10Y
23.06%
RETURN ON EQUITY (ROE) AVG 15Y
20.80%
RETURN ON EQUITY (ROE) AVG 20Y
19.38%
CURRENT VS TTM AVG
-63.71%
CURRENT VS 3Y AVG
-61.94%
CURRENT VS 5Y AVG
-60.36%
CURRENT VS 10Y AVG
-58.98%
CURRENT VS 15Y AVG
-54.53%
CURRENT VS 20Y AVG
-51.18%
SECTOR MEDIAN · HEALTHCARE
13.38%
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
-29.30%
vs the sector median at left
Edwards Lifesciences Corporation
Market Cap
$53.93B
Return on Equity (ROE)
9.46%
TTM Avg
26.07%
3Y Avg
24.86%
5Y Avg
23.86%
Market Cap
$56.27B
Return on Equity (ROE)
-14.61%
TTM Avg
-14.61%
3Y Avg
-32.42%
5Y Avg
4.78%
Market Cap
$49.99B
Return on Equity (ROE)
1.85%
TTM Avg
6.60%
3Y Avg
6.50%
5Y Avg
6.42%
Market Cap
$46.28B
Return on Equity (ROE)
70.67%
TTM Avg
60.82%
3Y Avg
72.53%
5Y Avg
81.69%
Market Cap
$64.96B
Return on Equity (ROE)
81.03%
TTM Avg
168.34%
3Y Avg
-32.99%
5Y Avg
148.52%
Market Cap
$42.22B
Return on Equity (ROE)
19.85%
TTM Avg
20.59%
3Y Avg
21.51%
5Y Avg
20.54%
Market Cap
$40.14B
Return on Equity (ROE)
22.28%
TTM Avg
21.77%
3Y Avg
21.17%
5Y Avg
17.55%
Market Cap
$72.37B
Return on Equity (ROE)
15.05%
TTM Avg
11.32%
3Y Avg
12.19%
5Y Avg
12.83%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation (EW) | $53.93B | 9.46% | 26.07% | 24.86% | 23.86% |
| Cardinal Health, Inc. (CAH)vs › | $56.27B | -14.61% | -14.61% | -32.42% | 4.78% |
| Becton, Dickinson and Company (BDX)vs › | $49.99B | 1.85% | 6.60% | 6.50% | 6.42% |
| IDEXX Laboratories, Inc. (IDXX)vs › | $46.28B | 70.67% | 60.82% | 72.53% | 81.69% |
| Humana Inc. (HUM)vs › | $44.77B | 6.65% | 7.05% | 11.93% | 15.09% |
| Cencora, Inc. (COR)vs › | $64.96B | 81.03% | 168.34% | -32.99% | 148.52% |
| Agilent Technologies, Inc. (A)vs › | $42.22B | 19.85% | 20.59% | 21.51% | 20.54% |
| IQVIA Holdings Inc. (IQV)vs › | $40.14B | 22.28% | 21.77% | 21.17% | 17.55% |
| Cigna Corporation (CI)vs › | $72.37B | 15.05% | 11.32% | 12.19% | 12.83% |
| DexCom, Inc. (DXCM)vs › | $33.79B | 38.14% | 28.93% | 25.01% | 22.95% |
ROE
9.5%
ROA
7.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 10.38% |
| 2024-12-31 | 41.75% |
| 2023-12-31 | 21.09% |
| 2022-12-31 | 26.21% |
| 2021-12-31 | 25.76% |
| 2020-12-31 | 18.00% |
| 2019-12-31 | 25.24% |
| 2018-12-31 | 23.00% |
| 2017-12-31 | 20.77% |
| 2016-12-31 | 21.74% |
| 2015-12-31 | 19.77% |
| 2014-12-31 | 37.01% |
| 2013-12-31 | 25.12% |
| 2012-12-31 | 19.82% |
| 2011-12-31 | 17.69% |
| 2010-12-31 | 16.66% |
| 2009-12-31 | 19.79% |
| 2008-12-31 | 14.67% |
| 2007-12-31 | 13.53% |
| 2006-12-31 | 17.41% |
| 2005-12-31 | 11.49% |
| 2004-12-31 | 0.27% |
| 2003-12-31 | 12.44% |
| 2002-12-31 | 10.33% |
| 2001-12-31 | -2.61% |
| 2000-12-31 | -61.82% |
| 1999-12-31 | 6.70% |
